Literature DB >> 22237433

Assessing the analytic validity of molecular testing for Huntington disease using data from an external proficiency testing survey.

Glenn E Palomaki1, C Sue Richards.   

Abstract

PURPOSE: Documenting high analytic validity of the molecular diagnostic test for Huntington disease is important because of counseling implications. This dominantly inherited adult onset disorder (prevalence of three or more per 100,000) is characterized by chorea, ataxia, and personality changes. The molecular basis is excessive CAG repeats in the HTT gene.
METHODS: External proficiency testing survey results for Huntington disease were extracted (2003-2010). Analytic interpretations and CAG repeat lengths were compared with published performance criteria.
RESULTS: Between 2008 and 2010, 33 US participating laboratories reported clinical test interpretations. Analytic validity was high (sensitivity: 99.5%, 95% confidence interval: 97.1-99.9%; specificity: 99.2%, 95% confidence interval: 97.1-99.9%). Repeat length errors occurred in 2.6% (95% confidence interval: 1.8-3.8%) of 1,060 allelic challenges, with most being minor or from a single participant. Past performance (2003-2007) was similar. The 23 international participants had more total repeat length errors (17.5%, 95% confidence interval: 14.6-20.7%). Further analyses indicated that assessment criteria can be relaxed without jeopardizing analytic validity.
CONCLUSION: Analytic validity is high for Huntington disease testing among US laboratories. International survey participants had lower analytic validity and a higher proportion of poorly performing laboratories. The reasons for this are unclear.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22237433     DOI: 10.1038/gim.0b013e3182310bb5

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  5 in total

Review 1.  Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics.

Authors:  Lisa V Kalman; Ira M Lubin; Shannon Barker; Desiree du Sart; Rob Elles; Wayne W Grody; Mario Pazzagli; Sue Richards; Iris Schrijver; Barbara Zehnbauer
Journal:  Arch Pathol Lab Med       Date:  2013-07       Impact factor: 5.534

2.  EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease.

Authors:  Monique Losekoot; Martine J van Belzen; Sara Seneca; Peter Bauer; Susan A R Stenhouse; David E Barton
Journal:  Eur J Hum Genet       Date:  2012-09-19       Impact factor: 4.246

3.  CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance.

Authors:  Devin Oglesbee; Tina M Cowan; Marzia Pasquali; Timothy C Wood; Karen E Weck; Thomas Long; Glenn E Palomaki
Journal:  Genet Med       Date:  2017-06-29       Impact factor: 8.822

4.  Detailed analysis of HTT repeat elements in human blood using targeted amplification-free long-read sequencing.

Authors:  Ida Höijer; Yu-Chih Tsai; Tyson A Clark; Paul Kotturi; Niklas Dahl; Eva-Lena Stattin; Marie-Louise Bondeson; Lars Feuk; Ulf Gyllensten; Adam Ameur
Journal:  Hum Mutat       Date:  2018-07-12       Impact factor: 4.878

5.  Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.

Authors:  Laura J Tafe; Michael B Datto; Glenn E Palomaki; Felicitas L Lacbawan
Journal:  Genet Med       Date:  2014-06-19       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.